The discovery of antiphospholipid antibodies (aPL) positivity in individuals who have never experienced thrombosis or pregnancy complications is not a rare event, and is one of the unresolved issues in the field of antiphospholipid syndrome (APS). This paper focuses on primary prophylaxis for thrombotic events in aPL carriers. In our view, patients with high risk aPL profiles and/or other cardiovascular risk factors, concomitant diagnosis of systemic lupus erythematosus (SLE) and patients with an history of obstetric APS (OAPS) should be offered thromboprophylaxis. Chronic thromboprophylaxis with low-dose aspirin and hydroxychloroquine in aPL positive SLE patients should be prescribed both to prevent thrombosis and to avoid early organ damage. Lupus (2012) 21, 751-754.
Introduction
The discovery of aPL positivity, due to a prolonged activated partial thromboplastin time (aPTT) or during routine screening in SLE and/or other autoimmune diseases, or before starting oral contraceptives and hormone replacement therapy, in individuals who have never experienced thrombosis and/or pregnancy complications is not a rare event. These are challenging cases as they represent one of the unresolved issues in the field of antiphospholipid syndrome (APS). A question arises: is it possible to predict which aPL positive patients will go on to develop clinical events? Presently there are no evidence-based answers in the management of aPL positive patients as reported by the APS Clinical Research Task Force during the 13th International Congress on Antiphospholipid Antibodies in Galvestone. 1 Whether prophylaxis is needed in aPL carriers is a very controversial matter and the topic has recently been extensively examined. 2, 3 This special article will discuss some reflections on this issue.
Thrombosis prevention
With regards to thrombosis prevention, we should differentiate between acute high risk situations, where prophylaxis is required for a brief period, and other situations that may require chronic prophylaxis.
Prophylaxis in high risk (acute) situations
An effective thromboprophylaxis is mandatory in patients with persistently positive aPL, even though there is a negative clinical history for APS, as high risk situations may trigger catastrophic APS (CAPS). 4 Surgical procedures are the most common precipitating factor for a thrombotic event 5 and, fortunately rarely, for CAPS. Other situations may include ovarian stimulation for ovulation induction, prepartum and puerperium period, long periods of immobilization and lupus associated skin lesions requiring thalidomide therapy. In lupus associated aPL positivity, other high risk situations to keep in mind are lupus flares, nephrotic syndrome and infections.
Chronic prophylaxis
Different subgroups of patients in need of chronic thromboprophylaxis have been identified. These include subjects with a high risk aPL profile Correspondence to: Maria Tiziana Bertero, Department of Clinical Immunology, Via Magellano N.1 10128 Torino, Italy Email: tbertero@mauriziano.it (lupus anticoagulant (LA), persistent medium/high titres anticardiolipin antibodies (aCL) and triple positivity for LA, aCL and antibodies to b2glycoprotein I (anti-b2GP I)) 6 and/or other cardiovascular risk factors, SLE and patients with a history of obstetric APS (OAPS). A high risk aPL profile 7 and the presence of other cardiovascular risk factors modulate the clinical expression of thrombosis; in this context, the report from the Task Force at the 13th International Congress on Antiphospholipid Antibodies recommends primary prophylaxis with aspirin along with obvious tailored lifestyle modifications. 6 Notably, hypertension seems to be a risk factor for both arterial and venous events. 8 In SLE aPL positive patients the annual risk of first thrombosis is higher when compared with healthy aPL positive subjects without other cardiovascular risks (4% vs. < 1%). 2 Hypercoagulability in SLE is attributable to multiple factors such as disease activity, accelerated atherosclerosis, immunomodulating drugs, infections, hypertension and nephritis. 9 Besides contributing to the prothrombotic state, the presence of aPL also predicts irreversible organ damage and a lower long-term survival in these patients. 10, 11 In fact, mortality is not always a direct consequence of thrombosis, suggesting that accrued irreversible damage makes patients more susceptible to other complications such as infections and a higher mortality.
Keeping in mind the different patterns of disease activity (fluctuating and modifiable by immunosuppression) and organ damage (progressive upward trend and irreversible) during the course of SLE, the sequence of events shown in Figure 1 could be hypothesized. In aPL positive SLE patients, disease flare-up predisposes to a thrombotic event. Thrombosis, in turn, favours an acceleration of organ damage. The correlation between thrombosis and damage is evident when evaluating organ damage, including cerebrovascular accident, pulmonary, myocardial and gastrointestinal infarction, venous thrombosis and tissue loss. 12 In aPL positive SLE patients, the consensus reached by the Task Force recommends thromboprophylaxis with low dose aspirin (LDA) and hydroxychloroquine (HCQ). Prophylactic treatment with LDA in SLE is controversial. The antiphospholipid antibody acetylsalicylic acid (APLASA) study showed no benefit 13 but the low risk aPL profile, the high percentage of autoimmune diseases at low risk of thrombosis and the short follow-up time make these data questionable. On the contrary, Tektonidou et al. reported a protective role for LDA in SLE. 14 In addition, despite the lack of evidence, the European league against rheumatism (EULAR) guidelines for the management of SLE recommend LDA as primary prophylaxis. 15 A recent study in a selected population of patients with triple aPL positivity showed that prophylaxis with LDA did not affect the incidence of events. 16 The multiple beneficial effects of HCQ in SLE are well known and reviewed in a recent paper. 17 Other than its direct effect in the prevention of flare-up, HCQ has shown to be effective in reducing cardiovascular risks such as hypercholesterolemia and diabetes. 18 Moreover, the ability of HCQ in preventing postoperative deep vein thrombosis in non-lupus patients has been known since the 1970s. 19 The use of antimalarials in SLE as reported by Jung et al. 20 has led to a reduction of thrombovascular events, both arterial and venous. In aPL positive patients, HCQ seems to be able to restore annexin A5 activity, reversing the effect of aPL at least in vitro, 21 making this drug a promising candidate for thromboprophylaxis in these patients. Primary thromboprophylaxis should also be considered in at least some cases of OAPS. A recent study showed that patients with OAPS have a higher thrombotic event rate than healthy women (3.3 vs. 0-0.5/100 patient-years), even if treated with low dose aspirin (LDA). 22 In our experience from the 'Piedmont APS cohort' (data not published), 13 out of 217 APS patients studied presented both vascular and obstetric manifestations. In 8 of these, unexplained deaths beyond the 10th week of gestation (Miyakis a) 23 or premature births before the 34th one (Miyakis b) 23 preceded the thrombotic events. We also noted a higher incidence of arterial events in our cohort (not treated with LDA) than in the Lefe`vre cohort. 22 We speculate that the subgroup of obstetric APS classified as Miyakis a and b are more exposed to risk of subsequent thrombosis than Miyakis c patients. On the basis of this hypothesis, we presently perform chronic thromboprophylaxis with LDA in OAPS Miyakis a and b, and with LDA and HCQ in OAPS associated to SLE.
Pregnancy morbidity prevention in aPL carriers
Pregnancy morbidity prevention in aPL carriers has not been a matter of many publications. We presently administer LDA in SLE aPL positive patients during pregnancy and LMWH during the postpartum period in all our patients, according to some authors' suggestions. 24, 25 However, data is scarce and more research is needed in this field.
Conclusions
Although evidence-based data is insufficient, we believe that particular groups of aPL positive subjects should be offered chronic thromboprophylaxis. These include those patients with a high risk aPL profile and/or other cardiovascular risk factors and SLE, and patients with a history of OAPS. Chronic prophylaxis with LDA and HCQ in aPL positive SLE patients should be prescribed both to prevent thrombosis and to avoid early organ damage.
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